MX2018003801A - Formulacion de hipericina para la terapia fotodinamica. - Google Patents

Formulacion de hipericina para la terapia fotodinamica.

Info

Publication number
MX2018003801A
MX2018003801A MX2018003801A MX2018003801A MX2018003801A MX 2018003801 A MX2018003801 A MX 2018003801A MX 2018003801 A MX2018003801 A MX 2018003801A MX 2018003801 A MX2018003801 A MX 2018003801A MX 2018003801 A MX2018003801 A MX 2018003801A
Authority
MX
Mexico
Prior art keywords
formulation
hypericin
photodynamic therapy
polyvinylpyrrolidone
therapy
Prior art date
Application number
MX2018003801A
Other languages
English (en)
Inventor
Welzig Stefan
Medinger Gregor
Kälz Beate
Gungl József
Gerdes Klaus
Frantsits Werner
Abrahamsberg Christina
Original Assignee
Sanochemia Pharmazeutika Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika Ag filed Critical Sanochemia Pharmazeutika Ag
Publication of MX2018003801A publication Critical patent/MX2018003801A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulación que puede usarse como fotosensibilizador en la terapia del cáncer, por ejemplo cáncer de vejiga, contiene sal de hipericina sódica complejada con polivinilpirrolidona o con polivinilpirrolidona,.
MX2018003801A 2015-09-28 2016-04-07 Formulacion de hipericina para la terapia fotodinamica. MX2018003801A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT6302015 2015-09-28
PCT/AT2016/000033 WO2017054017A1 (de) 2015-09-28 2016-04-07 Formulierung von hypericin zur photodynamischen therapie

Publications (1)

Publication Number Publication Date
MX2018003801A true MX2018003801A (es) 2018-11-09

Family

ID=55854522

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003801A MX2018003801A (es) 2015-09-28 2016-04-07 Formulacion de hipericina para la terapia fotodinamica.

Country Status (14)

Country Link
US (3) US10143751B2 (es)
EP (1) EP3237010B1 (es)
JP (1) JP6800231B2 (es)
KR (1) KR102194523B1 (es)
CN (1) CN108348609A (es)
AU (1) AU2016331656B2 (es)
BR (1) BR112018006043B1 (es)
CA (1) CA3000409C (es)
DK (1) DK3237010T3 (es)
ES (1) ES2750818T3 (es)
MX (1) MX2018003801A (es)
PL (1) PL3237010T3 (es)
RU (1) RU2018114867A (es)
WO (1) WO2017054017A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629932B2 (en) * 2015-09-28 2017-04-25 Sanochemia Pharmazeutika Ag Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method for the production and use thereof
EP3593815A1 (de) * 2018-07-13 2020-01-15 Planta Naturstoffe Vertriebsges.m.b.h. Hypericin-pvp komplex mit hohem hypericinanteil

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19756677A1 (de) 1997-12-19 1999-06-24 Krewel Meuselbach Gmbh Arzneipflanzentrockenextrakte
DE19814014A1 (de) 1997-12-19 1999-09-30 Krewel Meuselbach Gmbh Arzneipflanzentrockenextrakte
AT408835B8 (de) 2000-05-23 2002-07-25 Andreas Dipl Ing Dr Kubin Präparation von hypericin gebunden an polyvinylpyrrolidon (pvp) verschiedenen polymerisations- und vernetzungsgrades
CN101130082A (zh) * 2007-07-27 2008-02-27 许川山 具有携氧功能的新型光敏剂
WO2009066294A1 (en) 2007-11-20 2009-05-28 Hy Biopharma Inc. Device and method for photodynamic therapy
CN104415348A (zh) * 2013-08-27 2015-03-18 汪步海 一种放疗增敏剂及其制备方法
DE102014204138A1 (de) 2014-03-06 2015-09-24 Briu Gmbh Pharmazeutische Formulierung, Verfahren zur Herstellung der pharmazeutischen Formulierung und Infusionslösung sowie deren Verwendung als Medizinprodukt und/oder als Medikament

Also Published As

Publication number Publication date
KR102194523B1 (ko) 2020-12-24
RU2018114867A (ru) 2019-10-28
JP6800231B2 (ja) 2020-12-16
JP2018529768A (ja) 2018-10-11
US10265397B2 (en) 2019-04-23
EP3237010B1 (de) 2019-08-14
WO2017054017A1 (de) 2017-04-06
US10143751B2 (en) 2018-12-04
DK3237010T3 (da) 2019-11-11
BR112018006043B1 (pt) 2023-10-31
CA3000409C (en) 2021-05-25
US20180055934A1 (en) 2018-03-01
KR20180068996A (ko) 2018-06-22
ES2750818T3 (es) 2020-03-27
US10201609B2 (en) 2019-02-12
CA3000409A1 (en) 2017-04-06
AU2016331656B2 (en) 2019-07-04
EP3237010A1 (de) 2017-11-01
BR112018006043A2 (pt) 2018-10-09
AU2016331656A1 (en) 2018-05-10
US20180055935A1 (en) 2018-03-01
RU2018114867A3 (es) 2019-10-28
PL3237010T3 (pl) 2020-03-31
US20170087249A1 (en) 2017-03-30
CN108348609A (zh) 2018-07-31

Similar Documents

Publication Publication Date Title
IL290149A (en) Combined treatment for cancer
EP3651772A4 (en) ANTI-CANCER POLYTHERAPY
EP3368656A4 (en) TARGETED CANCER THERAPY
EP3180010A4 (en) Combination therapy for treating cancer
EP4324473A3 (en) Multiparametric nucleic acid optimization
HUE064857T2 (hu) Kombinációs terápia a rák ellen
EP3407978A4 (en) COMBINATION THERAPY FOR TREATING CANCER
EP3307240A4 (en) Combination therapy for the treatment of cancer
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
EP3285773A4 (en) POLY THERAPY FOR THE TREATMENT OF CANCER
EP3207162A4 (en) Combination therapy for use in cancer therapy
EP3359192A4 (en) POLY THERAPY FOR THE TREATMENT OF CANCER
EP3362066A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
HK1258319A1 (zh) 癌症療法
EP3193884A4 (en) Combination therapy for treating cancer
EP3131552A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
EP3541818A4 (en) PHOTOSENSITIZER
EP3362065A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
BR112018012116A2 (pt) terapia intravesical para câncer de bexiga
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
EP3675891A4 (en) ANTI-CANCER POLYTHERAPY
EP3256115A4 (en) COMBINATION CANCER THERAPY
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab
MX2018003802A (es) Formulacion de hipericina para el diagnostico fotodinamico.
MX2018003801A (es) Formulacion de hipericina para la terapia fotodinamica.